199 related articles for article (PubMed ID: 35820925)
1. Alternative splicing patterns reveal prognostic indicator in muscle-invasive bladder cancer.
AZhaTi B; Wu G; Zhan H; Liang W; Song Z; Lu L; Xie Q
World J Surg Oncol; 2022 Jul; 20(1):231. PubMed ID: 35820925
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
3. Characterization of alternative splicing events and prognostic signatures in breast cancer.
Han P; Zhu J; Feng G; Wang Z; Ding Y
BMC Cancer; 2021 May; 21(1):587. PubMed ID: 34022836
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Analysis of Alternative Splicing Signature in Gastric Cancer Prognosis Based on The Cancer Genome Atlas (TCGA) and SpliceSeq Databases.
Cheng X; Li X; Gu Y; Zhou L; Tang J; Dai X; Jiang H; Huang Y; Zhang Y; Xu T; Liu Z; Zhao Q
Med Sci Monit; 2020 Nov; 26():e925772. PubMed ID: 33219199
[TBL] [Abstract][Full Text] [Related]
5. Novel Insights Into Triple-Negative Breast Cancer Prognosis by Comprehensive Characterization of Aberrant Alternative Splicing.
Gong S; Song Z; Spezia-Lindner D; Meng F; Ruan T; Ying G; Lai C; Wu Q; Liang Y
Front Genet; 2020; 11():534. PubMed ID: 32595697
[TBL] [Abstract][Full Text] [Related]
6. Identification of survival-associated alternative splicing events and signatures in adrenocortical carcinoma based on TCGA SpliceSeq data.
Xu N; Ke ZB; Lin XD; Lin F; Chen SH; Wu YP; Chen YH; Wei Y; Zheng QS
Aging (Albany NY); 2020 Mar; 12(6):4996-5009. PubMed ID: 32217810
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
8. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
9. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
10. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
11. Development of prognostic signature based on immune-related genes in muscle-invasive bladder cancer: bioinformatics analysis of TCGA database.
Jin K; Qiu S; Jin D; Zhou X; Zheng X; Li J; Liao X; Yang L; Wei Q
Aging (Albany NY); 2021 Jan; 13(2):1859-1871. PubMed ID: 33465047
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
Li Y; Guo D
BMC Cancer; 2021 Aug; 21(1):958. PubMed ID: 34445990
[TBL] [Abstract][Full Text] [Related]
13. Novel insights into clear cell renal cell carcinoma prognosis by comprehensive characterization of aberrant alternative splicing signature: a study based on large-scale sequencing data.
Zhang D; Zhang W; Sun R; Huang Z
Bioengineered; 2021 Dec; 12(1):1091-1110. PubMed ID: 33783315
[TBL] [Abstract][Full Text] [Related]
14. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
Wan Q; Sang X; Jin L; Wang Z
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
16. Identification of an alternative splicing signature as an independent factor in colon cancer.
Chen H; Luo J; Guo J
BMC Cancer; 2020 Sep; 20(1):904. PubMed ID: 32962686
[TBL] [Abstract][Full Text] [Related]
17. Determining the prognostic significance of alternative splicing events in soft tissue sarcoma using data from The Cancer Genome Atlas.
Yang X; Huang WT; He RQ; Ma J; Lin P; Xie ZC; Ma FC; Chen G
J Transl Med; 2019 Aug; 17(1):283. PubMed ID: 31443718
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing events in tumor immune infiltration in renal clear cell carcinomas.
Wang Z; Zhu L; Li K; Sun Y; Giamas G; Stebbing J; Peng L; Yu Z
Cancer Gene Ther; 2022 Oct; 29(10):1418-1428. PubMed ID: 35370291
[TBL] [Abstract][Full Text] [Related]
19. Role of alternative splicing events in endometrial cancer prognosis.
Liu J; Mi C; Long W; Sun T
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 46(7):680-688. PubMed ID: 34382583
[TBL] [Abstract][Full Text] [Related]
20. A prognostic index based on a fourteen long non-coding RNA signature to predict the recurrence-free survival for muscle-invasive bladder cancer patients.
Zhang X; Zhang M; Zhang X; Zhu X; Wang J
BMC Med Inform Decis Mak; 2020 Jul; 20(Suppl 3):136. PubMed ID: 32646427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
